Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 2
1983 7
1984 11
1985 11
1986 6
1987 7
1988 6
1989 16
1990 19
1991 28
1992 40
1993 29
1994 25
1995 18
1996 17
1997 20
1998 21
1999 25
2000 24
2001 24
2002 13
2003 19
2004 27
2005 15
2006 20
2007 24
2008 21
2009 23
2010 19
2011 20
2012 21
2013 21
2014 20
2015 28
2016 27
2017 13
2018 23
2019 17
2020 63
2021 86
2022 81
2023 48
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

955 results

Results by year

Filters applied: . Clear all
Page 1
COVID-19-associated coagulopathy and disseminated intravascular coagulation.
Asakura H, Ogawa H. Asakura H, et al. Int J Hematol. 2021 Jan;113(1):45-57. doi: 10.1007/s12185-020-03029-y. Epub 2020 Nov 7. Int J Hematol. 2021. PMID: 33161508 Free PMC article. Review.
Rather than providing uniform treatment, the treatment method most suitable for the severity and stage should be selected. Combination therapy with heparin and nafamostat is expected to develop in the future. Fibrinolytic therapy and adsorption therapy require further stud …
Rather than providing uniform treatment, the treatment method most suitable for the severity and stage should be selected. Combination thera …
Antiviral effect and safety of nafamostat mesilate in patients with mild early-onset COVID-19: An exploratory multicentre randomized controlled clinical trial.
Okugawa S, Ikeda M, Kashiwabara K, Moritoyo T, Kohsaka T, Shimizu T, Hagiya H, Hasegawa K, Otsuka F, Miwa A, Kisimoto N, Mizoguchi A, Imamura A, Ikeuchi K, Tsutsumi T, Jubishi D, Hashimoto H, Okamoto K, Harada S, Inoue JI, Seto Y, Moriya K. Okugawa S, et al. Int J Antimicrob Agents. 2023 Sep;62(3):106922. doi: 10.1016/j.ijantimicag.2023.106922. Epub 2023 Jul 8. Int J Antimicrob Agents. 2023. PMID: 37429450 Free article. Clinical Trial.
The primary endpoint was area under the curve for decrease in SARS-CoV-2 viral load in nasopharyngeal samples from baseline to day 6. RESULTS: Of the 30 randomized patients, 19 received nafamostat. Overall, 10 patients received low-dose nafamostat, 9 patients receiv …
The primary endpoint was area under the curve for decrease in SARS-CoV-2 viral load in nasopharyngeal samples from baseline to day 6. RESULT …
Anticoagulation with nafamostat mesilate during extracorporeal life support.
Lang Y, Zheng Y, Qi B, Zheng W, Wei J, Zhao C, Gao W, Li T. Lang Y, et al. Int J Cardiol. 2022 Nov 1;366:71-79. doi: 10.1016/j.ijcard.2022.07.022. Epub 2022 Jul 16. Int J Cardiol. 2022. PMID: 35850387 Review.
Nafamostat mesylate (NM) affects coagulation and fibrinolysis and impedes obesity-associated protein demethylase activity, which regulates Na(+)/K(+) transport properties and the NF-kappaB signaling pathway. ...
Nafamostat mesylate (NM) affects coagulation and fibrinolysis and impedes obesity-associated protein demethylase activity, which regu …
A Randomized Trial of Nafamostat for Covid-19.
Morpeth SC, Venkatesh B, Totterdell JA, McPhee GM, Mahar RK, Jones M, Bandara M, Barina LA, Basnet BK, Bowen AC, Burke AJ, Cochrane B, Denholm JT, Dhungana A, Dore GJ, Dotel R, Duffy E, Dummer J, Foo H, Gilbey TL, Hammond NE, Hudson BJ, Jha V, Jevaji PR, John O, Joshi R, Kang G, Kaur B, Kim S, Das SK, Lau JSY, Littleford R, Marsh JA, Marschner IC, Matthews G, Maze MJ, McArthur CJ, McFadyen JD, McMahon JH, McQuilten ZK, Molton J, Mora JM, Mudaliar V, Nguyen V, O'Sullivan MVN, Pant S, Park JE, Paterson DL, Price DJ, Raymond N, Rees MA, Robinson JO, Rogers BA, Ryu WS, Sasadeusz J, Shum O, Snelling TL, Sommerville C, Trask N, Lewin SR, Hills TE, Davis JS, Roberts JA, Tong SYC. Morpeth SC, et al. NEJM Evid. 2023 Nov;2(11):EVIDoa2300132. doi: 10.1056/EVIDoa2300132. Epub 2023 Oct 18. NEJM Evid. 2023. PMID: 38320527 Clinical Trial.
A Randomized Trial of Nafamostat for Covid-19Nafamostat mesylate is a potent in vitro antiviral that inhibits the host transmembrane protease serine 2 enzyme used by SARS-CoV-2 for cell entry. Morpeth et al report the results of an open-label randomized clinical trial of …
A Randomized Trial of Nafamostat for Covid-19Nafamostat mesylate is a potent in vitro antiviral that inhibits the host transmembrane …
Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters.
Neary M, Sharp J, Gallardo-Toledo E, Herriott J, Kijak E, Bramwell C, Cox H, Tatham L, Box H, Curley P, Arshad U, Rajoli RKR, Pertinez H, Valentijn A, Dhaliwal K, Mc Caughan F, Hobson J, Rannard S, Kipar A, Stewart JP, Owen A. Neary M, et al. Viruses. 2023 Aug 15;15(8):1744. doi: 10.3390/v15081744. Viruses. 2023. PMID: 37632086 Free PMC article.
Clinically, nafamostat is limited to intravenous delivery and has an extremely short plasma half-life. ...Significantly lower SARS-CoV-2 RNA concentrations were seen in the nasal turbinates of the nafamostat-treated group compared to the control (p = 0.001). A plaqu …
Clinically, nafamostat is limited to intravenous delivery and has an extremely short plasma half-life. ...Significantly lower SARS-Co …
In Silico Analysis and Synthesis of Nafamostat Derivatives and Evaluation of Their Anti-SARS-CoV-2 Activity.
Fujimoto KJ, Hobbs DCF, Umeda M, Nagata A, Yamaguchi R, Sato Y, Sato A, Ohmatsu K, Ooi T, Yanai T, Kimura H, Murata T. Fujimoto KJ, et al. Viruses. 2022 Feb 14;14(2):389. doi: 10.3390/v14020389. Viruses. 2022. PMID: 35215982 Free PMC article.
In this study, we investigated crucial elements that cause the difference in anti-SARS-CoV-2 activity of nafamostat and camostat. In silico analysis showed that Asp435 significantly contributes to the binding of nafamostat and camostat to TMPRSS2, while Glu299 inter …
In this study, we investigated crucial elements that cause the difference in anti-SARS-CoV-2 activity of nafamostat and camostat. In …
Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study.
Kameda S, Fujii T, Ikeda J, Kageyama A, Takagi T, Miyayama N, Asano K, Endo A, Uezono S. Kameda S, et al. BMC Nephrol. 2023 Jan 16;24(1):12. doi: 10.1186/s12882-023-03060-1. BMC Nephrol. 2023. PMID: 36642717 Free PMC article.
This study aimed to determine whether heparin or nafamostat mesylate used during CKRT was associated with a longer filter life. ...RESULTS: We included 286 patients, 157 patients on heparin and 129 patients on nafamostat mesylate. After propensity score matching, th …
This study aimed to determine whether heparin or nafamostat mesylate used during CKRT was associated with a longer filter life. ...RE …
Delayed administration of nafamostat mesylate inhibits thrombin-mediated blood-spinal cord barrier breakdown during acute spinal cord injury in rats.
Zhao C, Zhou T, Zhao X, Pang Y, Li W, Fan B, Li M, Liu X, Ma L, Zhang J, Sun C, Shen W, Kong X, Yao X, Feng S. Zhao C, et al. J Neuroinflammation. 2022 Jul 16;19(1):189. doi: 10.1186/s12974-022-02531-w. J Neuroinflammation. 2022. PMID: 35842640 Free PMC article.
BACKGROUND: Nafamostat mesylate (nafamostat, NM) is an FDA-approved serine protease inhibitor that exerts anti-neuroinflammation and neuroprotective effects following rat spinal cord injury (SCI). ...METHODS: Time to first dose of nafamostat administration wa …
BACKGROUND: Nafamostat mesylate (nafamostat, NM) is an FDA-approved serine protease inhibitor that exerts anti-neuroinflammati …
Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review.
Hernández-Mitre MP, Tong SYC, Denholm JT, Dore GJ, Bowen AC, Lewin SR, Venkatesh B, Hills TE, McQuilten Z, Paterson DL, Morpeth SC, Roberts JA. Hernández-Mitre MP, et al. Clin Pharmacokinet. 2022 Oct;61(10):1331-1343. doi: 10.1007/s40262-022-01170-x. Epub 2022 Aug 30. Clin Pharmacokinet. 2022. PMID: 36040613 Free PMC article. Review.
Repurposing of drugs licensed for non-coronavirus disease 2019 (COVID-19) indications has been extensively investigated in laboratory models and in clinical studies with mixed results. Nafamostat mesylate (nafamostat) is a drug licensed in Japan and Korea for indica …
Repurposing of drugs licensed for non-coronavirus disease 2019 (COVID-19) indications has been extensively investigated in laboratory models …
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K, Meyerholz DK, Bartlett JA, McCray PB Jr. Li K, et al. mBio. 2021 Aug 31;12(4):e0097021. doi: 10.1128/mBio.00970-21. Epub 2021 Aug 3. mBio. 2021. PMID: 34340553 Free PMC article.
Both camostat and nafamostat reduced infection in primary human airway epithelia and in the Calu-3 2B4 cell line, with nafamostat exhibiting greater potency. ...We tested the hypothesis that inhibitors of these proteases, the serine protease inhibitors camostat and …
Both camostat and nafamostat reduced infection in primary human airway epithelia and in the Calu-3 2B4 cell line, with nafamostat …
955 results